Slow wave sleep (SWS) and the effect of African ancestry on amyloid burden, a longitudinal study

点击翻译按钮获取中文摘要

7. PROJECT SUMMARY/ABSTRACT: African-Americans (AAs) have an increased prevalence of Alzheimer's disease (AD) compared to whites, which traditionally has been associated to the presence of vascular disease. However, a recent community- based study of non-demented elderly, as well as our preliminary data, suggest that AAs have higher amyloid burden after adjusting for vascular risk factors, which points to the presence of additional genetic or physiological differences on AD-risk by race. The purpose of this study is to test whether poor slow wave sleep (SWS) is one of these factors. Sleep disturbances vary between AAs and non-Hispanic whites. AAs take longer to fall asleep, have shorter sleep duration, lower sleep efficiency and, more characteristically, less SWS duration when compared to whites. Relatedly, amyloid positive healthy elderly, as well as those with mild cognitive impairment (MCI) and AD, experience more sleep fragmentation and more decreased SWS and REM sleep duration than their healthy counterparts. This suggests: i) that disturbed sleep contributes to AD- neurodegeneration (or that sleep is particularly sensitive to amyloid deposition); and, ii) that race-related sleep differences might contribute to the reported increases in amyloid burden in AAs. The study has two goals: first, to confirm that black race is associated in vivo with longitudinal increases in amyloid-PET uptake and cognitive decline; second, to demostrate that poor SWS at baseline is associated with these increases after controling for the cardiovascular morbidity that is shared between sleep disturbances and dementia and might confound these associations. In consultation with community stakeholders, we will recruit 150 cognitively normal AA elderly (ages 55-75 years) and 60 whites balanced by age, sex, BMI, education and other socio- demographic variables and from the same Brooklyn neighborhoods. Visit one will include a full clinical evaluation, neuropsychological tests and clinical labs. Participants will later undergo home monitoring for OSA for two nights followed by 5 days of actigraphy. Subjects with normal sleep breathing will be invited to perform 2 nights of nocturnal polysomnography (NPSG) followed by a second final visit in which amyloid load and cerebrovascular morbidity will be analyzed by 11C-PiB PET-MR. All subjects will be invited to repeat both visits after 30 months. This study has the potential to identify clinical predictors of amyloid burden in cognitively normal AA elderly and would be an important step towards the prevention of dementia in the black community as well as the reduction of health inequities.